The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Insulin Aspart Injection insulin aspart Biosimilar | Masuu Pharma Europe Limited | Diabetes Mellitus | 🇪🇺 EU | Order → |
| Insulin Human 30/70 Mix Marvel insulin human | Marvel LifeSciences Ltd. | Diabetes Mellitus | 🇪🇺 EU | Order → |
| Insulin Human Long Marvel insulin human | Marvel LifeSciences Ltd. | Diabetes Mellitus | 🇪🇺 EU | Order → |
| Insulin Human Rapid Marvel insulin human | Marvel LifeSciences Ltd. | Diabetes Mellitus | 🇪🇺 EU | Order → |
| Insulin Human Rechon insulin human Biosimilar | Rechon Life Science AB | Diabetes Mellitus | 🇪🇺 EU | Order → |
| Ipique bevacizumab | Rotterdam Biologics B.V. | Wet Macular Degeneration | 🇪🇺 EU 2021-12-16 | Order → |
| Iplex mecasermin rinfabate | Insmed Europe Ltd | Dwarfism, Pituitary | 🇪🇺 EU | Order → |
| Isembyld apitegromab Orphan | Scholar Rock Netherlands B.V. | Muscular Atrophy, Spinal | 🇪🇺 EU | Order → |
| Isomarv medium insulin human | Marvel Life Sciences Ltd. | 🇪🇺 EU | Order → | |
| Issarlos strontium ranelate;colecalciferol | Les Laboratoires Servier | 🇪🇺 EU | Order → | |
| Istodax romidepsin Orphan | Celgene Europe Ltd. | Lymphoma, Non-Hodgkin | 🇪🇺 EU 2012-11-15 | Order → |
| Ixempra | Bristol-Myers Squibb Pharma EEIG | Breast Neoplasms | 🇪🇺 EU | Order → |
| IXinity trenonacog alfa | Cangene Europe Limited | Hemophilia B | 🇪🇺 EU | Order → |
| Izelvay avacincaptad pegol | Astellas Pharma Europe B.V. | Macular Degeneration; Geographic Atrophy | 🇪🇺 EU | Order → |
| Janacti | Merck Sharp Dohme Ltd. | 🇪🇺 EU | Order → | |
| Jelrix autologous cartilage-derived articular chondrocytes, in-vitro expanded ATMP | TETEC Tissue Engineering Technologies AG | Knee Injuries; Cartilage Diseases; Knee Joint | 🇪🇺 EU 2025-07-24 | Order → |
| Jenzyl | Merck Sharp and Dohme Ltd. | 🇪🇺 EU | Order → | |
| Jeraygo aprocitentan Additional monitoring | Idorsia Pharmaceuticals Deutschland GmbH | Hypertension | 🇪🇺 EU 2024-04-26 | Order → |
| Jesduvroq daprodustat | GlaxoSmithKline Trading Services Limited | Renal Insufficiency, Chronic; Anemia | 🇪🇺 EU | Order → |
| Jivadco trastuzumab duocarmazine | medac Gesellschaft für klinische Spezialpräparate mbH | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.